Research Paper Volume 15, Issue 16 pp 8090—8112
Identification of immunotherapy biomarkers for improving the clinical outcome of homologous recombination deficiency patients with lung adenocarcinoma
Figure 7. MS4A6A can be used as a potential biomarker for ICB treatment. (A) OS curves for high and low MS4A6A expression in the IMvigor210 cohort. (B) The proportion of immune response in MS4A6A high and low expression groups against ICB treatment. Abbreviations: CR: complete remission; PR: local response; SD: stable disease; PD: progressive disease. (C) Comparison of neoantigen load between different MS4A6A expression subgroups. (D, E) Comparison of MS4A6A expression among different immune responsive cohorts. (F) TIDE differences in MS4A6A high- and low-expression cohorts. (G–J) TCIA analysis of differences in IPS scores in MS4A6A high and low expression cohorts. *P < 0.05, **P < 0.01, ***P < 0.001.